Alpine Global Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Alpine Global Management’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-181,403	Closed	-$33.3M	–	447
2021 Q2	$33.3M	Buy	181,403 +13,846	+8%	+$2.38M	4.54%	3
2021 Q1	$25.6M	Buy	167,557 +162,557	+3,251%	+$25.1M	2.46%	11
2020 Q4	$781K	Buy	+5,000	New	+$643K	0.16%	74
2020 Q1	–	Sell	-56,238	Closed	-$6.08M	–	519
2019 Q4	$6.08M	Buy	+56,238	New	+$6.02M	1.3%	10
2017 Q4	–	Sell	-1,625	Closed	-$228K	–	294
2017 Q3	$228K	Buy	+1,625	New	+$221K	0.07%	166
2015 Q3	–	Sell	-1,014	Closed	-$183K	–	935
2015 Q2	$183K	Sell	1,014 -240	-19%	-$41.4K	0.03%	417
2015 Q1	$217K	Sell	1,254 -2,868	-70%	-$519K	0.07%	278
2014 Q4	$763K	Buy	+4,122	New	+$764K	0.14%	166

Other funds holding ALXN

BCI

Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return

NICM

Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return

TAIM

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CFO

CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return

MAM

Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Alpine Global Management's ALXN Position: Q3 2021 in Review

Alpine Global Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 181,403 shares — an estimated $33.3M sold.

Alpine Global Management first reported a position in ALXN in Q4 2014 and held it in 8 quarters. The position peaked at $33.3M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

Alpine Global Management reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Alpine Global Management sold 181,403 Alexion Pharmaceuticals shares in Q3 2021, an estimated $33.3M.
Alpine Global Management first reported a position in Alexion Pharmaceuticals in Q4 2014 and held it in 8 quarters.
Alpine Global Management's Alexion Pharmaceuticals position peaked at $33.3M in Q2 2021.
7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Alpine Global Management's 13F filing for Q3 2021, filed 12 Nov 2021.